Search in:

Pharmaceutical Biology Volume 59, 2021 - Issue 1

Submit an article Journal homepage

Open access

2,159

Views

CrossRef citations to date

Altmetric

Research Article

Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4⁺ type 9 helper T cells and the VIP–VPAC2 signalling pathway

Muhua Huanga Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China

https://orcid.org/0000-0001-9084-7739 View further author information

Jinfeng Wua Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, ChinaView further author information

Jingcheng Donga Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China;b Institute of Integrative Medicine, Fudan University, Shanghai, ChinaCorrespondence[email protected]

https://orcid.org/0000-0002-5194-367X View further author information

Pages 1214-1230 | Received 04 Feb 2021, Accepted 14 Aug 2021, Published online: 07 Sep 2021

Cite this article
https://doi.org/10.1080/13880209.2021.1970198
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (10)

Qing Kong, Bin Wang, Yuanyuan Zhong, Wenjing Chen, Jing Sun, Baojun Liu & Jingcheng Dong. (2024) Modified Bushen Yiqi Formula mitigates pulmonary inflammation and airway remodeling by inhibiting neutrophils chemotaxis and IL17 signaling pathway in rats with COPD. Journal of Ethnopharmacology 321, pages 117497.
Crossref

Qing Kong, Huahe Zhu, Weiyi Gong, Xiaohong Deng, Baojun Liu & Jingcheng Dong. (2024) Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice. Journal of Ethnopharmacology 319, pages 117183.
Crossref

Wenglam Choi, Yueren Wu, Yifan Li & Jingcheng Dong. (2023) Network pharmacology prediction and molecular docking analysis reveal the mechanism of modified Bushen Yiqi formulas on chronic obstructive pulmonary disease. The Journal of Gene Medicine 26:1.
Crossref

Hanlin Shi, Lingling Deng, Yaolong Zhou, Hang Yu, Xi Huang, Mengmeng Chen, Yang Lei & Jingcheng Dong. (2023) Network pharmacology and experiments in vivo and in vitro reveal that the Jia-Wei-Bu-Shen-Yi-Qi formula (JWBSYQF) and its active ingredient baicalein ameliorate BLM-induced lung fibrosis in mice via PI3K/Akt signaling pathway. Journal of Ethnopharmacology 315, pages 116691.
Crossref

Yixi Li, Wen Zhu, Rui Lin, Junjie Zhao & Yue Wang. (2023) Vasoactive intestinal peptide exerts therapeutic action by regulating PTEN in a model of Sjögren's disease. Immunity, Inflammation and Disease 11:7.
Crossref

Qing Kong, Yuxue Cao, Zhen Gao, Jing Sun, Hongying Zhang, Yijie Du, Yubao Lv, Sihan Zhou, Zihui Tang, Baojun Liu & Jingcheng Dong. (2022) Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial. Trials 23:1.
Crossref

Zeyu Meng, Huize Chen, Chujun Deng & Shengxi Meng. (2022) Potential cellular endocrinology mechanisms underlying the effects of Chinese herbal medicine therapy on asthma. Frontiers in Endocrinology 13.
Crossref

Bo-wen Zhou, Hua-man Liu & Xin-hua Jia. (2022) The Role and Mechanisms of Traditional Chinese Medicine for Airway Inflammation and Remodeling in Asthma: Overview and Progress. Frontiers in Pharmacology 13.
Crossref

Misato Irie, Kotaro Sasahara, David Artis & Hiroki Kabata. (2022) Current overview of the role of neuropeptides in ILC2s and future directions. Allergology International 71:3, pages 294-300.
Crossref

Katarzyna Kaczyńska, Dominika Zając, Piotr Wojciechowski & Monika Jampolska. (2021) Regulatory Peptides in Asthma. International Journal of Molecular Sciences 22:24, pages 13656.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4⁺ type 9 helper T cells and the VIP–VPAC2 signalling pathway

Articles from other publishers (10)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP–VPAC2 signalling pathway

Citations (10)

Articles from other publishers (10)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4⁺ type 9 helper T cells and the VIP–VPAC2 signalling pathway